NASDAQ:INVA - Innoviva Stock Price, News & Analysis

$11.39
-0.14 (-1.21 %)
(As of 09/17/2019 04:00 PM ET)
Today's Range
$11.34
Now: $11.39
$11.59
50-Day Range
$10.88
MA: $11.42
$11.90
52-Week Range
$10.76
Now: $11.39
$20.54
Volume47,857 shs
Average Volume422,283 shs
Market Capitalization$1.15 billion
P/E Ratio3.22
Dividend YieldN/A
Beta1.51
Innoviva, Inc engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a long-acting beta2 agonist (LABA), vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate (FF); ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA and LABA. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:INVA
Previous SymbolNASDAQ:THRX
CUSIP88338T10
Phone650-238-9600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$261 million
Cash Flow$4.0971 per share
Book Value$1.57 per share

Profitability

Net Income$395.05 million

Miscellaneous

Employees6
Market Cap$1.15 billion
Next Earnings Date10/30/2019 (Estimated)
OptionableOptionable

Receive INVA News and Ratings via Email

Sign-up to receive the latest news and ratings for INVA and its competitors with MarketBeat's FREE daily newsletter.


Innoviva (NASDAQ:INVA) Frequently Asked Questions

What is Innoviva's stock symbol?

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

How were Innoviva's earnings last quarter?

Innoviva Inc (NASDAQ:INVA) issued its quarterly earnings results on Wednesday, July, 24th. The biotechnology company reported $0.34 EPS for the quarter, missing analysts' consensus estimates of $0.43 by $0.09. The biotechnology company had revenue of $64.11 million for the quarter. Innoviva had a net margin of 146.60% and a return on equity of 307.49%. View Innoviva's Earnings History.

When is Innoviva's next earnings date?

Innoviva is scheduled to release their next quarterly earnings announcement on Wednesday, October 30th 2019. View Earnings Estimates for Innoviva.

Has Innoviva been receiving favorable news coverage?

Media headlines about INVA stock have been trending negative this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Innoviva earned a news sentiment score of -2.9 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Innoviva.

Are investors shorting Innoviva?

Innoviva saw a decrease in short interest in August. As of August 15th, there was short interest totalling 12,481,300 shares, a decrease of 11.3% from the July 15th total of 14,071,700 shares. Based on an average trading volume of 882,300 shares, the short-interest ratio is presently 14.1 days. Currently, 18.8% of the shares of the stock are sold short. View Innoviva's Current Options Chain.

Who are some of Innoviva's key competitors?

What other stocks do shareholders of Innoviva own?

Who are Innoviva's key executives?

Innoviva's management team includes the folowing people:
  • Mr. Geoffrey Hulme, Interim Principal Exec. Officer (Age 52)
  • Ms. Marianne Zhen CPA, Chief Accounting Officer (Age 50)
  • Mr. Jeffrey A. Hagenah Ph.D., Chief Patent Counsel and VP
  • Dr. Kevin Kwok, Head of Talent Acquisition & Strategy

Who are Innoviva's major shareholders?

Innoviva's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.44%), Vanguard Group Inc. (7.02%), Renaissance Technologies LLC (6.96%), LSV Asset Management (2.96%), Man Group plc (2.10%) and D. E. Shaw & Co. Inc. (1.93%). Company insiders that own Innoviva stock include Eric Desparbes, Geoffrey Hulme, George B Abercrombie, George Bickerstaff, Marianne Zhen, Michael W Aguiar and Theodore J Jr Witek. View Institutional Ownership Trends for Innoviva.

Which institutional investors are selling Innoviva stock?

INVA stock was sold by a variety of institutional investors in the last quarter, including Nomura Holdings Inc., Nomura Holdings Inc., Victory Capital Management Inc., WINTON GROUP Ltd, Invesco Ltd., Connor Clark & Lunn Investment Management Ltd., Pictet Asset Management Ltd. and Pictet Asset Management Ltd.. View Insider Buying and Selling for Innoviva.

Which institutional investors are buying Innoviva stock?

INVA stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Nuveen Asset Management LLC, Marshall Wace LLP, LSV Asset Management, Man Group plc, JPMorgan Chase & Co., Wells Fargo & Company MN and Balyasny Asset Management LLC. Company insiders that have bought Innoviva stock in the last two years include Geoffrey Hulme and George Bickerstaff. View Insider Buying and Selling for Innoviva.

How do I buy shares of Innoviva?

Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Innoviva's stock price today?

One share of INVA stock can currently be purchased for approximately $11.39.

How big of a company is Innoviva?

Innoviva has a market capitalization of $1.15 billion and generates $261 million in revenue each year. The biotechnology company earns $395.05 million in net income (profit) each year or $3.53 on an earnings per share basis. Innoviva employs 6 workers across the globe.View Additional Information About Innoviva.

What is Innoviva's official website?

The official website for Innoviva is http://www.inva.com/.

How can I contact Innoviva?

Innoviva's mailing address is 2000 SIERRA POINT PARKWAY SUITE 500, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]


MarketBeat Community Rating for Innoviva (NASDAQ INVA)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  259 (Thanks for Voting!)
Underperform Votes:  342 (Thanks for Voting!)
Total Votes:  601
MarketBeat's community ratings are surveys of what our community members think about Innoviva and other stocks. Vote "Outperform" if you believe INVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/17/2019 by MarketBeat.com Staff

Featured Article: CD Ladder

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel